The Effect of Inhibition of B7-mediated Costimulation on Allergic Airway Inflammation in Mild Atopic Asthmatics
Condition: Atopic Asthma
MeSH terms: Asthma
Intervention: abatacept; Placebo
Intervention description: Treatment with abatacept, 10 mg/kg IV, for 5 doses.; Treatment with Placebo, IV
Intervention MeSH terms: Abatacept
Phase: Phase 2
Study type: Interventional
Primary purpose: Basic Science
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Enrollment: 24.0
Sex: All
Minimum age: 18 Years
Maximum age: 50 Years
Healthy volunteers: No
Keywords: Asthma; Allergy

Summary:

      This study is designed to determine if treatment with abatacept is effective in decreasing
      allergic airway inflammation in mild, atopic asthmatics. Subjects will be recruited from the
      greater St Louis Metropolitan area. Eligible individuals will undergo a titrated skin prick
      test. Following baseline evaluation, fiberoptic bronchoscopy with segmental allergen
      challenge (SAC) will be performed. The subjects will be randomized to either placebo or
      abatacept. After 12 weeks of study drug, the subjects will undergo repeat SAC. The primary
      endpoint will be to determine if treatment with abatacept results in a 50% or greater
      decrease in the percentage of eosinophils recovered in the bronchoalveolar lavage (BAL) fluid
      following SAC as compared to placebo control. Secondary endpoints include measures of airway
      obstruction and hyperreactivity, airway inflammation and symptoms as well as determination of
      the safety of abatacept administration in this subject population.
    

Eligibility criteria:

        Inclusion Criteria:

        Subjects must meet all of the following criteria:

          1. 18 - 50 years of age;

          2. Previously documented physician-diagnosis of asthma consistent with NAEPP guidelines,
             with alternative diagnoses (eg, chronic obstructive pulmonary disease) ruled out;

          3. Forced expiratory volume in one second (FEV1) ≥ 70% of predicted value at screening
             and at first SAC visit;

          4. Positive methacholine inhalation challenge test of (PC20) ≤ 8 mg/mL within 6 months or
             at screening visit;

          5. History of atopic symptoms by subject self-report (allergic rhinitis, conjunctivitis,
             or eczema);

          6. A positive skin prick or intradermal test to cat allergen extract, short ragweed
             allergen extract, or dust mite allergen extracts at screening visit. A positive skin
             test is defined as induration of skin test wheal being ≥ 2 mm greater in diameter than
             saline control skin wheal;

          7. After the baseline SAC (V3), subject should demonstrate at least a 50% increase in the
             percentage of eosinophils (compared to pre-allergen saline) and at least 10%
             eosinophils in post allergen lavage.

          8. Stable asthma as reflected by no significant changes in controller asthma medications,
             no acute asthma exacerbations requiring oral corticosteroids, hospitalizations,
             emergency room visits, or unscheduled health care provider visits for asthma for at
             least 4 weeks prior to screening and up through the time of the first dose of study
             drug;

          9. No history of intubation for asthma;

         10. Sexually active women of childbearing potential must use an effective method of birth
             control during the entire course of the study and for 10 weeks after the final dose of
             the study drug, in a manner such that risk of failure is minimized. Prior to study
             enrollment, women of childbearing potential (WOCBP) will be advised of the importance
             of avoiding pregnancy during trial participation and the potential risk factors for an
             unintentional pregnancy. All WOCBP MUST have a negative pregnancy test on the day of
             drug administration prior to receiving each dose. If the pregnancy test is positive,
             the patient must not receive investigational product and must not be enrolled in the
             study. In addition, all WOCBP should be instructed to contact the Investigator
             immediately if they suspect they might be pregnant (e.g., missed or late menstrual
             period) at any time during study participation.

         11. Ability to give informed consent (adults must be able to consent for themselves and be
             literate) and to comply with study procedures.

        Exclusion Criteria:

        Patients must have none of the following:

          1. Lung disease other than allergic asthma (eg, chronic bronchitis, COPD);

          2. Use of chronic oral corticosteroids or inhaled corticosteroids at doses > 440 μg/da
             fluticasone or equivalent within four weeks prior to screening visit

          3. Concurrent diseases, finding on physical examination, or screening laboratory studies
             that, in the investigator's opinion, would interfere with participation in the study
             or that might put the participant at risk by participating;

          4. Upper or lower respiratory tract infections within 4 weeks before screening;

          5. No febrile illness (>38.0o C or 100.4oF) within 24 hours at screening and through the
             time of the study drug administration on Study Day 0;

          6. Current use of any β-adrenergic antagonist (eg, propranolol)

          7. Use of long acting beta-agonists (LABA) or long acting muscarinic antagonists (LAMA)
             within 2 weeks of screening visit.

          8. Use of theophylline preparations.

          9. Current allergy immunotherapy within 3 months of screening.

         10. Use of systemic immunosuppressive drugs including systemic corticosteroids ,within the
             4 weeks prior to screening up through administration of study drug;

         11. Use of any TNFα inhibitor within 12 weeks of administration of study drug.

         12. Participation in an intervention research study within past 4 weeks or receipt of any
             investigational drug or biologic(s) within 5 half-lives of the agent prior to the
             first dose of study drug and through Study Day 154;

         13. Evidence of infection with hepatitis B or C virus, or human immunodeficiency virus-1
             or 2 (HIV-1 or HIV-2), or active infection with hepatitis A;

         14. History of cancer other than basal cell carcinoma or cervical carcinoma-in-situ that
             has been treated and cured by conization or other techniques.

         15. History of primary immunodeficiency;

         16. History of use of tobacco products of more than one cigarette per month or equivalent
             within 1 year prior to screening or history of smoking of greater than or equal to 10
             pack-years;

         17. History of a positive PPD;

         18. History of allergic reaction to abatacept or any of the components of the study drug.

         19. Pregnancy, women that are breast feeding, or that have an intention to become pregnant
             or breast feed during the time frame of the study.